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SUMMARY 
 
Retinoic Acid (RA) induces neural differentiation of SH-SY5Y neuroblastoma cells. We 
show that the mRNA levels of the differentiation-inhibiting bHLH transcription factors 
ID1, ID2 and ID3 are downregulated during RA-induced differentiation of SH-SY5Y cells. 
The levels of ID proteins decreased in parallel to the observed transcriptional repression. 
The expression of other bHLH genes changed during RA-induced differentiation: 
expression of neuroblast-specific ASCL1 (HASH-1) gene was promptly reduced after RA 
treatment, whereas expression of differentiation-promoting genes NEUROD6 (NEX-1, 
HATH-2) and NEUROD1 was increased. Treatments with TPA, another inducer of 
neuroblastoma cell differentiation, also resulted in coordinated downregulation of ID gene 
expression, underscoring the role of ID genes in differentiation. Downregulation of ID gene 
expression by RA involves a complex mechanism, since full transcriptional repression 
required newly synthesized proteins and signaling by the Phosphatidylinositol-3 kinase. RA 
treatment activates the Phosphatidylinositol-3 kinase/Akt signaling pathway, resulting in 
increased Phosphatidylinositol-3 Kinase activity in extracts from RA-treated cells and a 
rapid increase in phosphorylation of Akt in Ser473. Inhibition of Phosphatidylinositol-3 
kinase by LY294002 impaired RA-induced differentiation, as assessed by morphological 
and biochemical criteria. We propose that RA, by activating the Phosphatidylinositol-3 
kinase/Akt signaling pathway, plays an important role in the regulation of neuronal cell 
survival. 
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INTRODUCTION 
 
Cell differentiation is a complex process regulated by an interplay between intrinsic cellular 
programs, cell-cell and cell-substrate interactions and a plethora of soluble extra-cellular 
signaling molecules, including hormones, growth factors, cytokines, trophic factors, morphogens, 
etc. Retinoic Acid (RA)1, the biologically active form of vitamin A, plays important role in early 
embryonic development and in the generation of several organs and systems, like it is the case of 
the nervous system (1-3, for review). In vitro, RA also plays a prominent role in regulating the 
transition from the proliferating precursor cell to the post-mitotic differentiated cell, and there are 
many examples in the literature of distinct cell types whose differentiation is under the control of 
RA (4-10).  
Two types of receptors, the RARs and the RXRs (11) mediate RA signaling. These 
receptors belong to the superfamily of the Nuclear Hormone Receptors, which function as ligand-
regulated transcription factors, and act modifying the transcriptional activity of specific genes 
(12, 13, for review). To elucidate the molecular mechanisms through which RA induces 
differentiation of neural cells, we have analyzed the changes in gene expression associated with 
RA-induced differentiation using human neuroblastoma cells as a model system. Neuroblastoma 
is a childhood tumor that arises from neural crest neuroectodermal cells (14, 15, for review). 
Despite their tumoral origin, neuroblastoma cell lines can be induced to differentiate in vitro by 
several agents, including RA (7, 16-18). In vitro differentiated neuroblastoma cells have a 
neuronal phenotype, as judged by their morphology and the expression of biochemical and 
functional neuronal markers. Therefore, neuroblastoma cells could be considered as an useful 
model system to study the initial phases of neuronal differentiation (19). RA derivatives are being 
employed in the therapy of neuroblastoma, and neuroblastoma patients treated with RA have 
increased survival rates (20, 21). Nevertheless, little is known about the molecular basis of the 
therapeutic effects of RA on neuroblastoma tumors.  
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Here we show that RA treatment of SH-SY5Y human neuroblastoma cells leads to 
changes in the expression levels of bHLH transcription factors, a gene family involved in the 
regulation of lineage commitment and cell differentiation in many cell types (22, for review). The 
products of ID genes act as dominant-negative inhibitors of differentiation by avoiding the 
binding of other bHLH transcription factors to their cognate DNA elements named E-boxes. RA 
treatment of SH-SY5Y neuroblastoma cells leads to a coordinated downregulation of the 
differentiation-inhibiting ID1, ID2 and ID3 genes. In addition, the expression of the neuroblast-
specific bHLH transcription factor ASCL1 (HASH-1) is rapidly reduced, and the mRNA levels of 
the differentiation-promoting bHLH factors NEUROD6 and NEUROD1 are increased. These 
results support the idea that RA treatment may induce differentiation by altering the balance 
between differentiation-inhibiting and differentiation-promoting bHLH factors.  
 The mechanism through which RA downregulates the ID gene expression appeared 
to be complex, since repression required newly synthesized proteins and the activity of 
Phosphatidyl-inositol-3 Kinase (PI3K). RA treatment rapidly activates the PI3K/Akt signaling 
pathway, which is a requisite for neuroblastoma cell differentiation, since treatment with PI3K 
specific inhibitor LY294002 impaired RA-induced differentiation. The results described here 
show evidence of novel actions of RA contributing to the induction of neural cell differentiation. 
In addition, the activation of PI3K/Akt signaling pathway by RA gives support for a heretofore 
unrecognized role of RA on the regulation of survival in neural cells, that provides a link between 
cell differentiation and cell survival.  
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EXPERIMENTAL PROCEDURES 
Cell Culture and treatments.  
SH-SY5Y human neuroblastoma cells were cultured in RPMI1640 medium with 10% fetal calf serum and 
0.15 mg/ml gentamycin sulfate in a humidified incubator at 37ºC with 5% CO2. The medium was replaced 
every 3 days and the cells were split before they reached confluence. RA (all-trans retinoic acid), TPA 
(phorbol 12-myristate, 13-acetate), cycloheximide and LY294002 (all from Sigma) were dissolved in 
ethanol or DMSO and added to the culture medium at the indicated concentrations.  
DNA probes 
Most of the DNA probes were inserts from EST-containing plasmids obtained from IMAGE Consortium 
(LLNL) (23). The IMAGE ID numbers for the different probes are 148057 (ID3), 235131 (ID1), 203370 
(ID2), 1032880 (ID4), 1569301 (ASCL1), 171864 (NEUROD6), 2518343 (NEUROD1), 610197 (GAP43), 
and 232714 (BCL2). RARB probe consisted in a 1.4 Kb DNA fragment containing the human RARβ2 
cDNA (24). MYC probe consisted of a 1.3 Kb genomic fragment containing human MYC exon 3 (25). 
Probes for NPY, ACTB and PPIA were generated by RT-PCR from RNA from SH-SY5Y cells. NPY probe 
was a 403 bp fragment, including nucleotides 5-407 of NPY cDNA (26). ACTB (actin beta) probe was a 183 
bp fragment, encompassing nucleotides 287-470 of the ACTB cDNA (27). PPIA (peptidylprolyl isomerase 
A, cyclophilin A) probe was a 415 bp fragment, including nucleotides 101-516 of the PPIA cDNA (28). 
Northern Blot  
Total RNA was obtained from PBS-washed cell monolayers by the method of Chomczynski and Sacchi 
(29). RNA (15-20 µg per lane) was denatured, electrophoresed through 1% agarose-formaldehyde gels and 
transferred to nylon membranes (NytranN45, Schleicher and Schuell) following standard techniques. DNA 
probes were labeled at high specific activity with [α32P]-dCTP (Amersham-Pharmacia Biotech, spec. 
act.>3000 Ci/mmol) by multiprime (RadPrime labeling system, Life Technologies). Hybridization was 
carried out overnight at 65°C according to Church and Gilbert (30). Filters were washed with 0.5xSSC, 
0.1% SDS, first at room temperature for 10 min, and then for 30 min at 65ºC. Membranes were exposed to 
X-ray films at -70ºC with intensifying screens.  
 
Nuclear Run-on transcription assay.  
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Preparation of nuclei. About 1-5x106 cells were lysated at 4ºC in 20 mM Tris-HCl, pH 8.0, 0.3 M Sucrose, 
60 mM KCl, 15 mM NaCl, 2 mM EDTA, 0.5 mM EGTA, 0.5 mM Spermidine, 0.15 mM Spermine, 0.5 
mM β-mercapto-ethanol and 0.1% Nonidet P-40. After washing with cold buffer B (50 mM HEPES-NaOH 
pH 8.0, 5 mM MgCl2, 0.5 mM DTT, 1 µg/ml Bovine Serum Albumin, 25 % Glycerol), nuclei were pelleted 
by centrifugation and carefully resuspended in the same buffer B. Aliquots of 50 µl containing 2-10x106 
nuclei were made, snap frozen in liquid nitrogen and stored at -80ºC.  
Preparation of the filters. 5 µg of linearized plasmids containing cDNA probe fragments (ID3, BCL2 and 
pBS-KS) or 1 µg of purified PCR fragments (ACTB, PPIA) were denatured with NaOH and neutralized by 
adding 10xSSC. Samples were applied to Nytran N45 membranes (Schleicher and Schuell) with the aid of 
a slot-blot apparatus (Minifold II, Schleicher and Schuell), and the DNA was fixed to the membrane by UV 
radiation.  
Run-on Transcription. Transcription reactions were set with 50 µl of Transcription mix (50 mM Hepes-
NaOH, pH 8.0, 2 mM MgCl2, 2mM MnCl2, 1 mg/ml Bovine Serum Albumin, 300 mM NH4Cl), 5 µl of 10 
mM CTP, ATP, GTP mix, 100 µCi [α-32P]-UTP (Amersham Pharmacia Biotech, spec. act. 800 Ci/mmol), 
40 u. RNAsin (Promega) and 50 µl of nuclei (2-10x106) in buffer B. After incubation for 20 min at 30ºC, 
nuclear DNA was digested with 10 u of RQ1 DNAse (Promega), and the labeled RNA purified according 
to Chomczynski and Sacchi (29). The RNA in the aqueous phase was precipitated twice with Isopropanol 
to eliminate the unincorporated nucleotide, and the RNA pellet was resuspended in DEPC-treated water. 
The incorporated radioactivity is estimated by measuring an aliquot in a scintillation counter (32P-
Cerenkov). Normally, 1-5x106 cpm/reaction are obtained.  
Hybridization. Filters were pre-hybridized in 2 ml of 200 mM sodium phosphate, pH 7.2, 1 mM EDTA, 7% 
SDS, 45% Formamide, 250 µg/ml yeast tRNA for 2-3 h at 42ºC, in a rotary oven. Equal amounts of labeled 
RNA probe obtained for each condition in 100 µl of DEPC-treated water were mixed with 1 vol of 99% 
Formamide, denatured at 65ºC, and chilled out on ice. The denatured probe was mixed with 2 ml of fresh 
hybridization solution, and added to the filters. Filters are hybridized for at least 40 h at 42ºC, and washed 
with 0.5xSSC, 0.1% SDS for 30 min at the hybridization temperature. Membranes were exposed to X-ray 
films at -70ºC with intensifying screens. 
Western blot.  
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Cell monolayers were washed with PBS, and lysated in RIPA buffer (50 mM HEPES pH 7.4, 150 mM 
NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 10 mM NaF, 1% TritonX100, 1% Deoxycholate, 0.1% 
SDS, 1mM sodium orthovanadate, 10 µg/ml Leupeptin, 10 µg/ml aprotinin, 100 µM PMSF). The extract 
was cleared by centrifugation at 4ºC and the protein content was determined with a detergent-compatible 
BioRad DC protein assay. Equal amounts of extracts were loaded to acrylamide SDS-PAGE gels according 
to Laemmli (31), and the electrophoresed proteins were electro-transferred to Nitrocellulose membranes 
(HybondECL, Amersham Pharmacia Biotech). Membrane was blocked with PBS, 0.1% Tween20 and 5% 
non-fat dry milk for at least 1 h. Membrane was incubated with the primary antibody in the above solution 
at 4ºC for 16 h. After washing with PBS-0.1% Tween20, the filter was incubated with horseradish 
peroxidase-conjugated secondary antibody in PBS, 0.1% Tween20 and 5% non-fat dry milk for 1 h at room 
temperature. Luminescent signal development with ECL (Amersham Pharmacia Biotech) was performed as 
recommended by the manufacturer. Filters were exposed to X-ray films in the dark. Antibodies against 
p110β subunit of PI3K, Akt, α-tubulin, ID1, ID2 and ID3 were purchased from Santa Cruz Biotechnology. 
Antibody against phosphorylated Akt was obtained from Cell Signal Technologies. Horseradish-
peroxidase-conjugated secondary antibodies were obtained from Amersham Pharmacia Biotech, Jackson 
ImmunoResearch and Santa Cruz Biotechnology.  
Electric Mobility Shift assay (EMSA) 
Cell pellets were frozen in liquid nitrogen and cells lysated in 10 mM HEPES, pH 7.9; 0.1 mM EDTA, 5% 
Glycerol, 400 mM NaCl, 1 mM DTT, 0.1 mM PMSF. The lysate was cleared by centrifugation and the 
protein content determined with the BioRad Protein assay. A double-stranded oligonucleotide E-box probe 
corresponding to the sequence present in the muscle creatine kinase enhancer was used for EMSA (MCKE; 
5': TCGACCCAACACCTGCTGCCGTACCAGCT-3', the E-box sequence shown in bold characters). The 
DNA probe was labeled by filling of the protruding ends with Klenow enzyme and [α-32P]-dCTP. The 
protein extracts (5 µg) were incubated in 12 µl of 20 mM HEPES pH 7.9; 100 mM NaCl, 0.1 mM EDTA, 1 
mM DTT, 20 % glycerol, 0.1% Triton X-100, containing 200 µg of bovine serum albumin, 2 µg of poly 
(dI-dC) and 50x103 cpm of the labeled MCKE probe. After 10 min incubation, the samples were loaded to 
a 6% poly-acrylamide gel in 0.5xTBE, and the gel run at 300 V for 2 h at 4°C. Finally, the dried gel was 
exposed to X-ray films.  
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PI3K assay.  
Cell monolayers were washed with ice-cold PBS, and cells were scraped off in 50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 10 mM NaF, 1mM sodium orthovanadate, 10µg/ml aprotinin, 10 µg/ml leupeptin, 0.1 mM 
PMSF and lysated by sonication. The extracts were cleared by centrifugation and total protein amount was 
measured (BioRad Protein Assay). Kinase reactions were set by mixing 20 µl of cell extract in lysis buffer 
(containing up to 40 µg of total protein), 20 µl of 0.5 mg/ml L-α-phosphatidyl-inositol (Sigma) in 10 mM 
HEPES pH 7.4, 0.1 mM EGTA and 10 µl of 50 mM HEPES pH 7.4, 25 mM MgCl2 containing 10 µCi of 
[γ-32P]-ATP (Amersham Pharmacia Biotech, spec. act 3000 Ci/mmol). When required, negative control 
reactions included 30 µM LY 294002. Reactions were incubated 10 min at room temperature, and were 
finished by adding 60 µl of 2 M HCl. Lipids were extracted with chloroform-methanol (1:1), and the 
organic phase loaded into a thin layer chromatography plate (Merck silica gel 60) pre-treated with 1% 
potassium oxalate in water. Chromatography was run in chloroform: methanol: 4M ammonia (9:7:2) until 
the front reached 80% of the plate. After drying, plates were exposed to X-ray films at -70ºC with 
intensifying screens. Quantification of the spots was made in a FUJI BAS phosphorimager.  
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RESULTS 
The expression of ID bHLH transcription factors is downregulated during RA-induced 
differentiation of SH-SY5Y human neuroblastoma cells.  
To characterize the molecular mechanisms through which RA triggers differentiation in 
SH-SY5Y cells, we analyzed differentially expressed genes using the Ordered Differential 
Display-PCR technique (32). Among several differentially expressed sequences obtained, one 
was identical to the 3' end of human ID3 mRNA. The profile obtained in the differential display 
gel showed elevated expression of ID3 in untreated cells, that was sustained after 8h of treatment 
with 1 µM RA but dropped sharply after 24 h of RA treatment (data not shown). Northern blot 
experiments confirmed the downregulation of ID3 mRNA during RA-induced differentiation 
(Fig. 1A), and nuclear run-on transcription experiments demonstrated a severe reduction of the 
transcription rate of ID3 gene accounting for the observed RA-induced downregulation (Fig. 1B). 
As different members of the ID gene subfamily of bHLH factors have been involved in the 
regulation of differentiation in many cell types (33, 34), we investigated whether other ID genes 
are expressed in SH-SY5Y neuroblastoma cells and how RA treatment could modify their 
expression levels. As shown in Figure 1C, ID1 was expressed in SH-SY5Y cells at levels 
comparable to those of ID3. ID2 mRNA levels appeared to be lower, since it was detected after 
longer exposures of the blots. ID4 mRNA was not detected in SH-SY5Y cells. Treatment of SH-
SY5Y cells with 1 µM RA resulted in downregulation of ID1 and ID2 expression, in parallel to 
the observed for ID3. Thus, RA treatment led to a coordinated downregulation of ID genes. The 
levels of ID1, ID2 and ID3 proteins in SH-SY5Y cells were severely reduced during RA 
treatment, in parallel to the observed changes in mRNA expression, as shown by western blot 
with specific antibodies (Fig. 1D).  
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RA treatment modified the expression pattern of bHLH transcription factors involved in 
neuronal differentiation.  
 ID proteins bind to and sequester ubiquitous E-proteins, avoiding complex formation 
with tissue-specific bHLH proteins and precluding heterodimer binding to E-box DNA elements. 
Treatment of SH-SY5Y cells with RA resulted in an increase of the protein complexes bound to 
an E-box element in gel-shift experiments (Fig. 2A), compatible with the observed decrease in the 
amounts of inhibitory ID proteins. We have analyzed the expression of bHLH genes involved in 
neuronal commitment and differentiation during the course of RA-induced neuronal 
differentiation of SH-SY5Y cells. As shown in figure 2B, the mRNA levels of ASCL1, a gene 
involved in determination of the neuronal fate expressed in proliferating neuroblasts (35), were 
reduced rapidly after RA treatment. On the other hand, expression of two members of the atonal 
subfamily of neurogenic bHLH factors was detected. The mRNA levels of NEUROD6 (NEX-1, 
Hath-2) are very abundant and increased rapidly after RA administration. Small amounts of 
NEUROD1 transcript were detected induced by RA. The mRNAs for other bHLH factors like 
neurogenin and ATOH1 were not detected (data not shown). As marker for neuronal 
differentiation and E-box-regulated gene we have assayed the expression of GAP43. Levels of 
GAP43 transcript were very low in untreated cells, and increased during RA-induced 
differentiation, reaching maximal expression after 24 h of treatment. In summary, differentiation 
induced by RA led to dramatic changes in the expression patterns of bHLH transcription factors 
in SH-SY5Y cells. In addition to downregulation of ID genes, RA treatment repressed the 
transcription of ASCL1, a neuroblast-specific gene, and activated the expression of at least two 
proneural genes from the atonal subfamily, NEUROD6 and NEUROD1. In parallel, the 
transcription of a bHLH-regulated, neuron-specific gene like GAP43 is upregulated.  
 
 
ID genes are downregulated during TPA-induced differentiation of SH-SY5Y cells. 
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 Phorbol esters are Protein Kinase C activators that have been reported to induce 
neural differentiation in several neuroblastoma cell lines (16). We have investigated whether the 
expression levels of the ID genes are modified during TPA-induced differentiation of SH-SY5Y 
cells. As shown in Figure 3, the levels of ID3, ID1 and ID2 mRNAs are maintained after 6 h of 
treatment with 100 nM TPA, but sharply reduced between 6 and 24 h of differentiation, with a 
similar kinetics to that observed with RA treatment. In addition, TPA induced transiently ID4 
expression. Low levels of ID4 mRNAs could be detected after 6 h of treatment, but were reduced 
later during TPA-induced differentiation. The expression of the major ID genes is thus 
coordinately downregulated during differentiation induced by two disparate compounds like RA, 
a signal acting through a Nuclear Hormone Receptor, and TPA, an activator of Protein Kinase C, 
underscoring the relevance of the downregulation of ID genes for terminal differentiation of 
neuroblastoma cells.  
 
Downregulation of the ID genes by RA requires newly synthesized proteins and Phosphatidyl-
inositol 3-kinase activity.   
 Next we investigated the molecular mechanisms of RA-induced coordinated 
downregulation of the ID genes. The fact that downregulation of the ID genes expression takes 
place between 6-24 h after administration of RA, with a considerable delay in respect to other 
downregulated genes like MYC (see Fig.1A), does not argue in favor of a direct regulation of the 
transcription of ID genes by ligand-activated RAR/RXR heterodimers. In addition, RA and TPA, 
two agents that normally have opposite effect on gene transcription, have similar effects on the 
expression of the major ID genes, supporting an indirect transcriptional regulation mechanism. 
Treatment of SH-SY5Y cells with cycloheximide, an inhibitor of protein synthesis, prevented 
downregulation of ID1 and ID3 expression by RA, without affecting transcriptional activation of 
genes directly activated by RA, like RARB. (Fig. 4A), supporting the idea that newly synthesized 
proteins are required for repression of ID genes by RA.  
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Since Phosphatidyl-inositol 3-Kinase (PI3K) signaling pathway has been involved in 
differentiation of many cell types, we have studied the effect of LY294002, a specific inhibitor of 
PI3K, on RA-induced repression of ID gene expression. As shown in figure 4B, treatment with 
LY294002 prevented RA-induced full downregulation of ID3 and ID1 gene expression in SH-
SY5Y cells, without affecting the induction of other genes directly activated by RA (data not 
shown). These results indicate that repression of ID genes by RA requires a signaling pathway 
involving PI3K. 
 
Activation of the PI3K/Akt signaling pathway by RA is required for neuronal differentiation of 
SH-SY5Y cells.  
RA treatment of SH-SY5Y cells resulted in sustained activation of PI3K as demonstrated 
by the corresponding in vitro kinase assay performed with total cellular extracts. (Fig. 5A). 
Treatment with RA for 24 h resulted in a four-fold increase in PI3K activity, which lasted up to 
48 h. This increase was abrogated when the assay was performed in the presence of LY294002 
(Fig. 5B). This sustained increase of PI3K activity correlated with an increase in the levels of the 
catalytic subunit of the enzyme, p110β, as shown by western blot with specific antibodies (Fig. 
5C). This increase appears to be consequence of an effect of RA on the stability of the protein, 
since a parallel increase in p110β mRNA was not detected (data not shown). Akt kinase is one of 
the major targets of PI3K. Treatment of SH-SY5Y neuroblastoma cells with RA resulted in rapid 
phosphorylation of the Akt kinase in Ser473 (Fig. 5D). Increased phosphorylated Akt 
immunoreactivity was detected as soon as after 30 min of RA treatment, and increased further to 
reach a maximum after 2-3 h of RA treatment. The level of Ser473-Akt phosphorylation obtained 
by RA treatment was comparable to that observed by heat-shock treatment (45°C, 30 min), a 
known inducer of Akt phosphorylation in SH-SY5Y cells (36).  
Next we have addressed whether the inhibition of PI3K by its specific inhibitor 
LY294002 would impair RA-induced differentiation. This was evaluated both morphologically, 
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by estimating the percentage of cells bearing long neurites, and biochemically, by analyzing the 
transcriptional activation of the neuron-specific gene GAP43. RA-induced morphological 
differentiation, shown by an increase in the percentage of cells bearing long neurites, was 
inhibited by addition of LY294002 (Fig. 6A). Treatment of the cells with the PI3K inhibitor 
resulted in a moderate increase in GAP43 mRNA basal level. However further transcriptional 
activation of GAP43 by RA was prevented by treatment with LY294002 (Fig. 6B). 
Transcriptional activation of the anti-apoptotic gene BCL2 was also impaired by treatment with 
LY294002 (Fig. 6C). Transcription of BCL2 is strongly activated during RA-induced 
differentiation. Again a moderate increase of BCL2 mRNA basal level could be observed in 
LY294002-treated cells. However, the inhibitor prevented RA-induced upregulation of BCL2. 
Taken together, these results indicate that activation of PI3K/Akt signaling pathway by RA is 
required for RA-induced cellular differentiation and for the transcription genes involved in the 
regulation of cell survival.  
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DISCUSSION 
The members of the bHLH family of transcription factors are involved in the control of 
commitment, differentiation and development of many different tissues and organs, including the 
nervous system (22, 37, 38, for a review). This control is often the result of the balance between 
differentiation-promoting and differentiation-inhibiting bHLH factors. ID genes encode 
dominant-negative bHLH proteins that are supposed to inhibit differentiation by counteracting the 
actions of differentiation-promoting bHLH proteins (33, 34,  for a review). Here we show that ID 
gene expression is coordinately downregulated during RA-induced differentiation of SH-
SY5Yneuroblastoma cells, and that ID protein levels follow a parallel decrease. In many cell 
types and experimental systems the expression of ID genes could be associated to active 
proliferation, and ID genes mRNA levels are downregulated during differentiation. Conversely, 
ectopic expression of ID genes leads to increased proliferation and to a block in differentiation 
(33, 34). Reduced expression of ID1 and ID3 in double knockout mutant mice leads to impaired 
development of the nervous system, with premature cell differentiation and aberrant expression of 
proneural bHLH genes (39). ID proteins bind to and sequester ubiquitous E-proteins, avoiding 
complex formation with tissue-specific bHLH proteins and activation of E-box-regulated genes 
involved in cell differentiation. Downregulation of ID gene expression by RA treatment of 
neuroblastoma cells would increase the amount of free bHLH factors ready to form functional 
heterodimers and bind to E-box elements. This idea is supported by the RA-dependent increased 
complex formation on an E-box element shown in the gel-shift experiment (Fig.2A), although 
this experiment is not conclusive. In addition, RA treatment leads to an increase in the expression 
of bHLH factors from the atonal subfamily (like NEUROD1 and NEUROD6), that eventually 
may contribute to counteract the inhibition of DNA binding and the block in differentiation 
imposed by ID factors. The expression of factors from the atonal subfamily might be sufficient to 
initiate the differentiation process, since ectopic expression of this class of bHLH factors has been 
reported to be sufficient to produce neural differentiation of ectoderm cells (40) and 
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neuroblastoma cells (41). The actions of these transcription factors would be also responsible for 
the transcriptional activation of neuron-specific genes, like GAP43, encoding a protein present in 
the growth cones of post-mitotic neurons, whose transcription is regulated through E-box 
sequences present at its promoter (42). On the other hand, the expression of ASCL1 (HASH-1), 
the human orthologue of mouse MASH1, is rapidly reduced during RA treatment. MASH1 is 
expressed in developing sympathetic neuronal precursors and is crucial for neuronal fate 
determination and development of olfactory neurons, sympathetic ganglia and some enteric and 
parasympathetic neuron populations (43, 44). During human fetal development, ASCL1 is 
expressed in sympathetic neuroblasts and its expression decays at the onset of the formation of 
sympathetic ganglia and paraganglia (35). ASCL1 is expressed in neuroblastoma cell lines and a 
majority of primary neuroblastoma tumors (35, 45-47). Our results are in good agreement with 
recent reports showing a decrease in ASCL1 mRNA levels during neuroblastoma cell 
differentiation (45, 47, 48), suggesting that downregulation of ASCL1 may be necessary to 
promote neuronal differentiation of neuroblastoma cells. Taken together, our results suggest that 
the differentiation signal elicited by RA could be transduced to the proneural bHLH network of 
transcription factors, via the downregulation of the ID gene expression. The reduction in the 
levels of differentiation-inhibiting ID factors induced by RA, would allow the differentiation-
promoting atonal bHLH transcription factors NEUROD1 and NEUROD6 act as effector genes of 
the differentiation signal initiated by RA, and these actions would result in the transcriptional 
activation of neuron-specific genes, like has been shown for GAP43.  
In addition, we have shown that treatment with TPA, another of the compounds that 
induce neuroblastoma cell differentiation (16), also results in the coordinated downregulation of 
ID gene expression. The fact that two distinct differentiating stimuli, like RA and TPA, that 
normally act through very different molecular mechanisms and generally have opposite 
transcriptional effects (49, 50), result in coordinated downregulation of ID gene expression 
underscores the role of ID gene in differentiation. This fact, together with the delayed kinetics of 
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downregulation, implies that the molecular mechanisms underlying ID gene coordinated 
repression might be complex. Coordinated downregulation of ID genes by RA appears to be 
indirect and requires newly synthesized proteins. In addition, we show that the PI3K/Akt 
signaling pathway is involved in RA-induced transcriptional downregulation of ID genes, since 
treatment with LY294002, a specific inhibitor of PI3K, prevented full repression of the ID genes 
by RA. The signaling pathway of PI3K/Akt is involved in regulating differentiation in many cell 
types. The similarities between the differentiation process in myoblasts and in neuroblastoma 
cells are striking. In both cases transcription factors from the bHLH family are involved, and 
activation of NF-κB and Nitric Oxide production take place in differentiating myoblasts (51), as 
well as in differentiating neuroblastoma cells (52, 53), suggesting that the molecular events 
regulating cell differentiation in both cell types might be similar. As activation of the PI3K/Akt 
pathway plays a crucial role in myoblast differentiation, and inhibition of PI3K activity by 
LY294002 abrogates differentiation (54), we considered the possibility that this signaling 
pathway could be involved in neuroblastoma cell differentiation. We have shown that RA 
treatment leads to a strong (four-fold) activation of PI3K activity in SH-SY5Y cells. Activation is 
detected after 24 h RA treatment and is maintained up to 48 h of differentiation. The observed 
increase of PI3K catalytic subunit p110β protein level during RA treatment might collaborate to 
this rather sustained activation of PI3K.  Nevertheless, this increase in p110β protein level 
appears to be originated by a post-translational effect, since the amount of p110β mRNA remains 
unchanged. A similar effect on p110β during mouse adipocyte differentiation has been reported 
(55). The protein kinase Akt is one of the targets of PI3K. Here we show that RA treatment leads 
to a rapid activation of Akt, and phosphorylation of Akt in Ser473 could be detected as soon as 
after 30 min of RA treatment. Akt kinase plays an important role in the regulation of cell death 
and survival (56, 57, for review). In addition, our results indicate that activation of the PI3K/Akt 
signaling pathway by RA is required for RA-induced differentiation, since inhibition of PI3K by 
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its specific inhibitor LY294002 resulted in a block of differentiation, according to morphological 
and biochemical criteria. Neurite extension, that became evident in RA-treated SH-SY5Ycells, is 
not observed when neuroblastoma cells were treated with RA in the presence of LY294002. In 
addition, transcriptional activation of the neural marker gene GAP43 did not took place in the 
course of RA-induced differentiation when PI3K was inhibited. Taken together, these results 
indicated that activation of the PI3K/Akt signaling pathway by RA is necessary for RA-induced 
differentiation of SH-SY5Y neuroblastoma cells. However, we do not believe that activation of 
this signaling pathway could be sufficient for differentiation. Recently, it has been shown that 
SH-SY5Y cells transiently transfected with a constitutively active form of PI3K did not become 
differentiated, and only a rather modest neurite outgrowth could be detected2. This idea is also 
supported by the fact that treatment with IGF-I, a potent activator of PI3K, does not induce 
differentiation of SH-SY5Y cells, but act as a mitogen. However, IGF-I cooperates strongly with 
RA or TPA in inducing cell differentiation (17, 58), effect that could be now better understood 
taking into account the results shown in this paper. An important question that arises from the 
results shown here is the nature of the  molecular mechanism by which RA activates PI3K. The 
typical activators of PI3K act through tyrosine kinase receptors, like is the case for IGF, PDGF, 
FGF, neurotrophins etc., and some of these factors promote neuroblastoma cell differentiation in 
vitro (17, 18). As the usual action of RA is transcriptional regulation, we initially thought that RA 
might induce the expression of a tyrosine kinase receptor, and we have examined several 
candidate genes (data not shown). However, on the basis of the rapid RA-induced 
phosphorylation of Akt, we put forward the idea that RA may activate PI3K through an atypical 
extra-genomic action of its receptor. A growing number of extra-genomic actions of Nuclear 
Hormone Receptors have been reported (59, 60, for review). It has been reported that estradiol 
activates PI3K through extra-genomic actions of its receptor ER in endothelial cells (61-63), in 
cortical neurons in culture (64), and in a cell line derived from a mammary tumor (65). In 
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addition, activation of PI3K by vitamin D3, through an extra-genomic action of VDR has been 
reported to be involved in myeloid cell differentiation (66).  
The results shown here support a heretofore unrecognized role for RA in the regulation of 
apoptosis and survival in neural cells. In neuroblastoma cells, RA-induced transcriptional 
activation of the anti-apoptotic gene BCL2 and increased resistance to apoptosis-inducing drugs 
has been reported (67-69). Effects of RA on the promotion of cell survival have been also 
reported for primary cultures of neuroblasts from spinal cord (70, 71), and for neurons derived 
from neural stem cells in vitro (72). Our results provide a molecular mechanism explaining the 
effects of RA on neural cell survival. Integration of the genomic and extra-genomic actions of RA 
results in coupling of cell differentiation and survival. On one hand, RA acts regulating the 
transcription of specific genes involved in cell differentiation. On the other hand, RA activates 
through an extra-genomic action the PI3K/Akt signaling pathway, which is involved in the 
regulation of survival. However, both types of actions do not occur independently, but are 
intertwined. Activation of the PI3K/Akt signaling pathway by RA also contributes to the 
transcriptional regulation of genes crucial for differentiation, as we have shown for the 
coordinated downregulation of the ID genes. Reciprocally, RA may contribute to cell survival by 
activating the transcription of genes encoding receptors for neurotrophic factors, like trk, trkB and 
RET3 (73-76). The PI3K/Akt signaling pathway is involved in the regulation of both 
differentiation and survival during RA-induced differentiation of neuroblastoma cells. However, 
this does not appear to be the case in PC12 pheochromocytoma cells, another well-characterized 
model system for neural differentiation, since regulation of differentiation and survival by NGF 
occurs via two independent signaling pathways. Differentiation requires activation of RAS/ERK 
pathway and survival requires the activation of PI3K/Akt pathway (77, 78).  
The coordinated regulation of cell differentiation and survival by RA may play an 
important role in the context of neuronal cell generation, in which an excess of precursor cells are 
produced to ensure that all the required nervous connections take place. With this neurotrophic 
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strategy (79, for review), those cells that establish contact with their target cells will receive from 
them neurotrophic survival factors, whereas those cells that do not succeed in finding their targets 
will die through apoptosis. The coupling between cell differentiation and survival elicited by RA 
may result in avoiding a premature cell death, allowing survival of the newly differentiated cell 
for a limited time period, until the contacts with its target cells could be established.  
RA and other synthetic retinoids are used frequently in the therapy of neuroblastoma 
tumors (20, 21), and other cancer types (80, for review). Another question arising from the results 
described here is that activation of the PI3K/Akt signaling pathway by RA leading to an increase 
of the resistance to cell death could be an unfavorable effect for cancer therapy. This could be 
especially important if RA treatment must be combined with therapies based on induction of cell 
death, like chemo-or radiotherapy. A possible solution for this problem would be the generation 
of synthetic retinoids lacking the ability to activate the PI3K/Akt pathway, which could have 
advantages as anticancer therapy.  
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FOOTNOTES 
1 The abbreviations used are: RA, all-trans Retinoic Acid; RAR, Retinoic Acid Receptor; RXR, 9-
cis Retinoic Acid Receptor; bHLH, basic domain helix-loop-helix transcription factor; PI3K, 
Phosphatidyl-inositol-3 Kinase; TPA, Phorbol 12-myristate 13-acetate; PBS, Phosphate-buffered 
saline; DEPC, Diethyl-pyrocarbonate; PMSF, Phenyl-methyl-sulfonyl-fluoride; PAGE, Poly-
acrylamide gel electrophoresis; EMSA, Electric mobility shift assay; MCKE, muscle creatinine 
kinase enhancer; NF-κB, Nuclear factor κB; ER, Estrogen Receptor; VDR, Vitamin D Receptor; 
PIP3: Phosphatidyl-inositol (3, 4, 5)-triphosphate.  
2 F. Wandosell, personal communication. 
3 López-Carballo G. et al., work in preparation.  
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LEGEND TO FIGURES 
 
Figure 1.  
Expression of ID genes is downregulated during RA-induced differentiation.  
(A) Northern blot Analysis. Each lane contains 15 µg of total RNA from SH-SY5Y 
neuroblastoma cells treated with 1 µM RA for the times indicated in the figure. The blot was 
sequentially hybridized with [32P]-labeled DNA probes specific for the mRNAs for RARβ 
(RARB, 3 Kb), c-myc (MYC, 2.5 kb), ID3 (1.2 Kb), and cyclophilin A (prolyl-peptidyl-isomerase 
A, PPIA, 1 Kb) as internal loading control.  
(B) Run-on assay of ID3 transcription rate. Nuclei from SH-SY5Y neuroblastoma cells treated for 
24 h with vehicle (-) or 1 µM RA (+) were used to generate [32P]-labeled run-on transcription 
probes. These probes were hybridized to nylon membranes containing 5 µg of ID3 probe plasmid 
DNA. As controls the filter also contained 5 µg of BCL2 probe plasmid DNA and 1 µg of purified 
actin β (ACTB) and cyclophilin A (PPIA) probes generated by PCR. Filters included 5 µg of 
pBluescript-KS (pBS-KS) as specificity control.  
(C) Coordinated downregulation of ID genes by RA. Northern blot Analysis. Each lane contains 
15 µg of total RNA from SH-SY5Y neuroblastoma cells treated with 1 µM RA for the times 
indicated in the figure. The blot was sequentially hybridized with [32P]-labeled DNA probes 
specific for the mRNAs for ID3 (1.2 Kb), ID1 (1.2 Kb) and ID2 (1.4 Kb). The 28S ribosomal 
RNA band in the blot stained with methylene blue is shown as internal loading control.  
(D) Western blot analysis. Each lane contains 20 µg of protein extract from SH-SY5Y 
neuroblastoma cells treated with 1 µM RA for the times indicated in the figure. The blot was 
sequentially incubated with specific antibodies raised against ID3, ID1 and ID2 proteins. As 
loading control, the membrane was incubated finally with antibodies against α-tubulin (α-tub).  
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Figure 2. 
The expression pattern of bHLH transcription factors involved in neuronal differentiation 
is modified during RA treatment  
(A) Electric mobility shift assay (EMSA). A [32P]-labeled double-stranded oligonucleotide probe 
containing the E-box element present in the Muscle Creatin Kinase Enhancer was incubated with 
5 µg of protein extract from SH-SY5Y neuroblastoma cells treated with 1 µM RA for the times 
indicated. The complexes formed were resolved in a 6% poly-acrylamide gel run in 0.5xTBE. 
(B) Northern blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells 
treated with 1 µM RA for the times indicated. The blot was sequentially hybridized with [32P]-
labeled DNA probes specific for the mRNAs for ASCL1 (2.6 Kb), NEUROD6 (1.4 Kb) 
NEUROD1 (4.2 Kb) and GAP43 (1.4 Kb). The 28S ribosomal RNA band in the blot stained with 
methylene blue is shown as internal loading control.  
 
Figure 3. 
Downregulation of ID genes during TPA-induced differentiation 
Northern blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells treated 
with 100 nM TPA for the times indicated. The blot was sequentially hybridized with [32P]-labeled 
DNA probes specific for the mRNAs for ID3 (1.2 Kb), ID1 (1.2 Kb), ID2 (1.4 Kb), ID4 (4.0, 2.8, 
and 1.7 Kb), NPY (1 Kb) and MYC (2.5 Kb). The 28S ribosomal RNA band in the blot stained 
with methylene blue is shown as internal loading control.  
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Figure 4 
Coordinated downregulation of the ID genes by RA requires newly synthesized proteins and 
the activity of the Phosphatidyl-inositol 3-kinase.  
(A) Northern blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells 
treated with 1 µM RA for the times indicated (left panel) or pre-treated for 30 min with 
cycloheximide (10 µg/ml) and then treated with 1 µM RA in the presence of the inhibitor for the 
times indicated (right panel). The blot was sequentially hybridized with [32P]-labeled DNA probes 
specific for the mRNAs for ID3 (1.2 Kb), ID1 (1.2 Kb), and RARB (3 Kb). The 28S ribosomal 
RNA band in the blot stained with methylene blue is shown as internal loading control. 
(B) Northern blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells 
treated with 1 µM RA for the times indicated (left panel) or pre-treated for 30 min with 
LY294002 (10 µM) and then treated with 1 µM RA in the presence of the inhibitor for the times 
indicated (right panel). The blot was sequentially hybridized with [32P]-labeled DNA probes 
specific for the mRNAs for ID3 (1.2 Kb), and ID1 (1.2 Kb). The 28S ribosomal RNA band in the 
blot stained with methylene blue is shown as internal loading control.  
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Figure 5 
Activation of the Phosphatidyl-inositol 3-kinase/Akt signaling pathway by RA 
(A) Phosphatidyl-inositol 3-kinase Assay. Phosphatidyl-inositol 3-kinase assay was performed 
with L-α-phosphatidyl-inositol, [γ-32P]-ATP and 40 µg whole cell protein extract from SH-SY5Y 
cells treated with 1 µM RA for the times indicated in the figure. As specificity control, a parallel 
assay was performed in the presence of 30 µM LY294002. The figure shows a detail of the 
autoradiogram of the thin layer chromatography plate, demonstrating a RA-induced increase in 
the generation of Phosphatidyl-inositol (3, 4, 5)-triphosphate (PIP3). The experiment was 
repeated five times with different amounts of protein extracts, and similar results were obtained. 
The figure shows a representative experiment. 
(B) Quantification of the assay shown in (A). The figure shows the quantification of the 
radioactivity present in the spots shown in (A). PI3K activity is shown as percent of the activity 
obtained for the untreated control extract.  
(C) Western blot analysis. Each lane contains 20 µg of protein extract from SH-SY5Y 
neuroblastoma cells treated with 1 µM RA for the times indicated in the figure. The blot was 
incubated with specific antibodies raised against p110β, the catalytic subunit of the Phosphatidyl-
inositol 3-kinase.  
(D) Immunodetection of Phosphorylated Akt. Each lane contains 20 µg of protein extract from 
SH-SY5Y neuroblastoma cells treated with 1 µM RA for the times indicated in the figure. Lane 
labeled HS contains 20 µg of protein extract from SH-SY5Y neuroblastoma cells submitted to a 
heat shock (45°C, 30 min). The blot was sequentially incubated with specific antibodies raised 
against Akt phosphorylated at Ser473 (P-Akt) and against total Akt (Akt).  
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Figure 6 
Activation of the PI3K/Akt signaling pathway by RA is required for neuronal 
differentiation of SH-SY5Y cells. 
(A) Morphological differentiation. We considered as morphologically differentiated those cells 
that bear neurites longer than twice the size of the cell body. The morphology of living SH-SY5Y 
neuroblastoma cells was examined under the inverted microscope, and the percentage of 
differentiated cells determined for cells treated with vehicle (Control), treated for 24 h with 10 
µM LY 294002 (LY), treated for 24 h with 1 µM RA (RA), and pre-treated for 30 min with 10 
µM LY 294002 and treated for 24 h simultaneously with 1 µM RA and 10 µM LY 294002 
(RA+LY). A minimum of 100 cells per dish is examined. The graph shows the results (expressed 
as mean ± standard deviation) of an experiment performed in triplicate.  
(B) Northern blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells 
treated with 1 µM RA for the times indicated (left panel) or pre-treated for 30 min with 
LY294002 (10 µM) and then treated with 1 µM RA in the presence of the inhibitor for the times 
indicated (right panel). For better comparison of basal levels 15 µg of total RNA from cells 
treated with vehicle was included in the right panel (lane labeled 0) The blots were hybridized 
with a [32P]-labeled DNA probe specific for the mRNA for GAP43 (1.4 Kb). The 28S ribosomal 
RNA band in the blot stained with methylene blue is shown as internal loading control. 
(C) Northern blot. Each lane contains 15 µg of total RNA from SH-SY5Y neuroblastoma cells 
treated with 1 µM RA for the times indicated (left panel) or pre-treated for 30 min with 
LY294002 (10 µM) and then treated with 1 µM RA in the presence of the inhibitor for the times 
indicated (right panel). The blots were hybridized with a [32P]-labeled DNA probe specific for the 
mRNA for BCL2 (7.6 Kb). The 28S ribosomal RNA band in the blot stained with methylene blue 
is shown as internal loading control. 
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